Atlas
FDA inspections evaluate your quality systems, documentation, and risk posture. This 100-point checklist covers what investigators actually review on site, from ALCOA+ data integrity to training records, equipment qualification, and clinical trial oversight.
Atlas
Unexo, an over-the-counter drug manufacturer, faced FDA scrutiny during a two-week inspection in May 2024. Investigators Nicole Knowlton and Kellia Hicks documented 12 observations, from missing batch records to a hole in the ceiling of the IPQA area.
Atlas
Effective CAPA is the difference between a fix that holds and a repeat 483 observation. This 2025 guide covers the full CAPA lifecycle, from root cause analysis to effectiveness checks, and shows how quality teams stay audit-ready under tighter FDA scrutiny.
Atlas
The FDA's January 2025 draft guidance, "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products," sets out a risk framework, disclosure requirements, and credibility standards for AI models used in drug development.
Atlas
MCP is an open standard that lets AI systems connect securely to data, apps, and services. For pharma and medical device leaders, it can speed trial design, improve regulatory visibility, and break down data silos, but it also creates new security and validation challenges.
Atlas
The shift from paper to electronic logs (eLogs) and electronic batch records (eBMRs) is accelerating across pharma manufacturing.
Atlas
AI can help generate procedures and Root Cause Analysis (RCA) reports, but AI-generated documents are not automatically FDA-compliant. Compliance depends on system design, data provenance, human oversight, and validation.
Atlas
Yes, LLM-based quality systems can pass an FDA Part 11 audit, but only with validation of intended use, controlled inputs and outputs, ALCOA+ data integrity, audit trails, rigorous change control, and human oversight. This guide walks through the controls and artifacts you need.
Atlas
MCP (Model Context Protocol) is a rapidly adopted open standard that lets AI agents securely and consistently access company data, tools, and workflows.
Atlas
MCP can support near-real-time decision-making across global R&D hubs without compromising compliance, but only with secure architecture, strong governance, and risk-based regulatory strategy. This post covers the blueprint, risks, and operational benefits.
Atlas
Regulatory intelligence, when integrated with a modern quality ecosystem (digital QMS, MES, MCP, CAPA analytics, and AI), can materially reduce repeat FDA Form 483 observations by turning reactive fixes into systemic prevention.
Atlas
FDA inspections expose weaknesses in documentation, training, CAPA follow-through, and transparency. This post covers eight of the most common mistakes quality teams make during inspections and the practical solutions that prevent them.
Atlas
eCTD v4.0 is a structural and data-driven upgrade to the electronic Common Technical Document, changing how dossiers are built, indexed, and delivered.
Atlas
A Corrective Action Request (CAR) is how quality teams drive accountability when a nonconformity hits. This guide covers CAR levels, the step-by-step process, common implementation challenges, and how to prevent repeat findings.
Atlas
FDA warning letters create real risks for pharma investors: production disruption, import alerts, recalls, legal costs, and delayed approvals. This post breaks down how regulators escalate, what the market reacts to, and the checklist to run before investing.
Atlas
Atlas delivers proactive alerts on FDA inspections, 483s, warning letters, recalls, and enforcement events. New data typically arrives within a business week, through proprietary market intelligence, before it's on the FDA website.
Atlas
Getting hit with an FDA Form 483 should be a wake-up call. As these observations are often made public, your company is under a tangible risk of losing...
Atlas
In an industry known for medical innovation, the pharmaceutical sector also faces growing scrutiny over its environmental impact and compliance...
QSIT inspections drill into four quality subsystems with a top-down logic: management controls, CAPA, design controls, and production and process controls. This guide shows quality teams how to prepare before the FDA walks in.
Finding the right FDA Form 483 fast is hard when no single government database holds them all. This guide walks through FOIA, third-party tools, and faster alternatives so quality teams can see what investigators are citing across the industry.
Atlas
An Establishment Inspection Report is created after FDA investigators inspect facilities involved in manufacturing, processing, or distributing...
Atlas
cGMP is the regulatory backbone of drug manufacturing quality. This guide walks through the core components, certification steps, common compliance challenges, and real-world examples every quality team should understand.
Every FDA inspection ends with an NAI, VAI, or OAI classification. This guide explains how investigators arrive at each, the common triggers, and the practices quality teams use to stay out of enforcement.
Atlas
When a quality team learns who's assigned to their site, the first thing they do is search the investigator by name. Atlas has 6,000+ FDA investigator reports covering inspection history, focus areas by CFR code, and how citation patterns have evolved.
Atlas
In October 2020, KVK-Tech, a pharmaceutical manufacturer, received a stern warning from the FDA. This was not the first time the company had been under...
Atlas
The FDA released 76 new Product-Specific Guidances, including 64 for drugs without approved generics and 29 for complex products. This guide breaks down how quality, compliance, and regulatory teams should use PSGs to reshape development plans, validation, and ANDA strategy.
Atlas
Facing an FDA inspection? For businesses in regulated industries such as pharmaceuticals, medical devices, or food production, that moment can define...
The FDA issued over 4,000 Form 483s in FY 2024. This guide shows quality teams how to search the Warning Letters Database, interpret citations, and use past violations to strengthen their own compliance program.
Atlas
The FDA issued an import alert targeting GLP-1 ingredients to stop counterfeit and substandard raw materials. This post covers what the alert does, how it affects global suppliers, and what quality teams need to change to keep market access.
Atlas
Medical device manufacturers have to navigate FDA device classification, 510(k) clearance, PMA, 21 CFR Part 820 (QSR), labeling and UDI requirements, and post-market surveillance. This post walks through each piece and the common compliance challenges.
Atlas
Between 2024 and 2025, the FDA shifted from pandemic-era stop-start inspection tactics to a sustained, more aggressive, data-driven, and technology-enabled oversight posture for foreign facilities.
Atlas
GxP covers the full spectrum of Good Practices, from manufacturing to pharmacovigilance. This guide explains the key components, compliance challenges, and how modern tools help pharma and medical device quality teams stay audit-ready.
Atlas
Unqualified suppliers cause violations, poor materials, and costly recalls. This guide walks quality teams through a structured supplier qualification process, the regulations that apply, and how to monitor performance over time.
Atlas
Most FDA inspection risks come from missed guidance updates, fragmented monitoring, and lack of evidence that regulatory changes were tracked. A dedicated guidance monitoring database like Hedwig centralizes global guidance, tracks updates and withdrawals, and creates inspection-ready evidence of continuous monitoring.
Atlas
In 2025, pharma and medical device quality assurance is going through a major shift. Continuous monitoring allows near-real-time tracking of manufacturing processes, while generative AI validation brings smarter risk detection and faster compliance. This post covers what's changing, what regulators expect, and how Atlas fits in.
Atlas
FDA inspections are high-stakes for pharma and medical device companies, yet most teams prepare with scattered data and spreadsheets. Atlas gives quality teams 700,000+ inspections, 6,000+ investigator reports, and an AI copilot to turn regulatory data into actionable preparation.
Atlas
Supplier compliance has become a strategic priority for pharma and medical device companies. Atlas real-time alerts notify quality teams via email and WhatsApp the moment a supplier or external manufacturer gets inspected, receives a 483, or gets a warning letter.
Atlas
Regulators update rules constantly and SOPs drift. This post covers how LLMs like GPT-4 detect contradictions between internal SOPs and regulatory requirements, what the benefits look like, and the risks teams need to manage.
Atlas
MCP cuts human error in clinical data management and regulatory reporting. It standardizes data interactions, automates processing, enables near-real-time validation, and creates detailed audit trails, so teams ship faster with fewer mistakes.
Atlas
By 2025, manufacturers, distributors, and most pharmacies must comply with DSCSA serialization, verification, and tracing requirements. Here's a plain-language breakdown of the rules, the enforcement timeline, and how quality teams track compliance.
Atlas
In 2025, the principles of ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available, Traceable) are...
Atlas
Model Context Protocol (MCP) is improving pharmacovigilance by enabling near-real-time data sharing, faster signal detection, and fewer manual errors in adverse event reporting. This post explains how MCP connects safety databases, regulatory systems, and AI tools in a secure, auditable layer.
Atlas
Data silos slow pharma and medical device R&D, causing inefficiencies and errors. MCP enables AI systems to access and integrate data across departments securely, streamlining workflows and accelerating decision-making.
Atlas
Yes. MCP (Model Context Protocol) can build a standardized data layer that bridges silos across sponsors, CROs, and regulators in multinational trials.
Atlas
Model Context Protocol turns ELNs, LIMS, MES, and QMS into discoverable, auditable interfaces for AI agents. For QA teams, it means fewer transcription errors, tamper-resistant audit trails, stronger ALCOA+ provenance, and faster root-cause work during FDA and EMA investigations.
Atlas
Pharma and medical device QA teams still fight version mismatches, manual evidence collation, and slow inspection responses. Model Context Protocol connects AI agents to MES, LIMS, QMS, and document repositories in a governed way, so audit-ready bundles, provenance, and semantic search become standard.
Atlas
The EU AI Act takes full effect in August 2026. This post covers the risk classification, the compliance building blocks (governance, documentation, oversight, conformity assessments), and a multi-year roadmap for global product and compliance teams.
Atlas
FDA inspection reports are often months behind on the FDA website and trapped in unsearchable PDFs. Atlas gives quality teams sub-second access to 700,000+ inspections since 2010, with advanced filters for investigator, CFR code, site type, and more.
Atlas
FDA Form 483 observations flag GMP non-compliance during inspections. Common issues involve equipment qualification, documentation, process validation, training, and facility controls. Prevent them through proactive management, internal audits, and better data access.
Atlas
FDA warning letters are public notices of regulatory non-compliance. They freeze new drug approvals, invite follow-up inspections, and damage reputation. This post covers the consequences and the CAPA-driven response that reduces long-term impact.
Atlas
AI-driven inspection models will enable FDA audits to be faster, more data-driven, and more focused on high-risk signals.
Atlas
The Model Context Protocol (MCP) is an emerging open standard that lets large generative models connect securely with external data sources, tools, and workflows. In drug design, it helps AI access lab data and structure libraries in a standardized, auditable way, though full readiness still depends on validation and governance.
Atlas
The FDA has rolled out major changes for medical device manufacturers, from QMSR alignment with ISO 13485 to stronger cybersecurity requirements, a risk-based SaMD framework, expanded post-market surveillance, and a refined 510(k) pathway. This guide breaks down what each change means in practice.
Atlas
AI is no longer experimental, and GDPR enforcement is accelerating. This post covers the governance basics that hold up in audit: lawful basis, DPIAs, monitoring limits, hallucination controls, and a practical checklist for the next 30 days.
Atlas
MCP gives AI systems a standard way to access regulated data and tools. For pharma research, that means AI outputs become reproducible, traceable, and easier for regulators to verify, while cutting integration effort and human error.
Atlas
Artificial intelligence has already improved how research is carried out in pharma and medical devices, but the real challenge comes when we try to scale these models beyond the lab and into commercial manufacturing. MCP offers a standardized way to bridge that gap.
Atlas
Non-conformance costs more than compliance. Learn how to detect, manage, and prevent it before it leads to inspection failures.
Atlas
Pharmaceutical regulatory compliance spans the full drug lifecycle, from IND to post-market surveillance. This guide covers the major regulatory bodies, core standards, and practical strategies quality teams use to stay audit-ready across FDA, EMA, and global markets.
FDA Pre-Approval Inspections decide whether your product ships on time or stalls. This guide covers triggers, objectives, and a step-by-step readiness plan so quality teams can walk investigators through the facility with confidence.
Atlas
Quality Assurance (QA) teams are the silent guardians of compliance in regulated industries. Yet, many organizations overlook the key metrics that reflect...
Atlas
The Supplier Corrective Action Request (SCAR) process is crucial for product quality and supplier accountability in Quality Management Systems (QMS).
Atlas
Pharma companies can automate regulatory submission workflows by combining comprehensive submission platforms, data standards (eCTD and emerging v4.
Atlas
In 2025, CBER approved new biological products and devices while issuing guidance on gene therapy, laboratory developed tests, and IVDR compliance. Here's what pharma and medical device quality teams need to know about the year's key approvals and regulatory shifts.
Atlas
Quality teams considering Atlas usually ask the same ten questions: what's in it, who it's for, how fresh the data is, and what makes it different from Redica. This post answers all of them directly, with the numbers and customer names to back each answer.
Atlas
An EDMS centralizes document storage, enforces version control, and keeps regulated teams audit-ready. This guide covers core features, benefits, and how to pick the right system for pharma and medical device operations.
Atlas
A CAPA program is how the FDA judges your quality system. This guide covers the six-step CAPA process, what investigators look for during inspections, and the common challenges teams face in execution.
Atlas
Change control is how regulated teams manage project modifications without breaking compliance. This guide covers the four types of change control, a six-step process, and a pharma manufacturing example showing it in action.
Atlas
A consent decree is the FDA's final stop before litigation. This guide explains what triggers one, how companies respond, the real business impact, and how quality teams can avoid reaching that point.
Atlas
In the pharmaceutical industry, even minor oversights can lead to significant compliance failures. The Corrective and Preventive Actions (CAPA) process is...
Atlas
Out-of-specification (OOS) results can halt production and trigger FDA action. This guide covers what OOS means, common causes, the two-phase investigation process, and how quality teams manage them without missing a beat.
Atlas
Discover what quality control is and the essential methods used. Learn about inspection, SPC, and tools like Pareto charts.
Atlas
The FDA runs about 12,000 domestic and 3,000 foreign inspections a year. This warehouse readiness checklist walks through structural integrity, hygiene, hazard management, and inspection-day protocols so your team stays calm, compliant, and audit-ready.
Atlas
The Model Context Protocol (MCP) is a new standard that allows AI models to connect easily with data, systems, and tools.
Atlas
The FDA's expectations for SaMD (Software as a Medical Device) submissions have shifted to a total product life cycle (TPLC) model emphasizing risk, data governance, human factors, and post-market monitoring. This guide breaks down what reviewers now expect, especially for AI/ML-enabled devices.
Atlas
FDA Form 483 observations and Warning Letters point to the same recurring root causes: data integrity lapses, weak quality systems (CAPA and investigations), incomplete batch records, training gaps, and equipment controls. This post breaks down each category and what QA teams can do about them.
Atlas
CAPA effectiveness is central to product quality, patient safety, and regulatory compliance in pharma and medical devices. This guide walks through the seven load-bearing CAPA metrics, verification plans, governance layers, and a sample dashboard leaders can adapt.
Atlas
Model Context Protocol gives AI agents a standardized way to reach ELNs, LIMS, QMS, and regulatory systems. It also introduces prompt injection, IP exfiltration, over-privileged delegation, and GxP audit-trail gaps that pharma and medical device teams must design around from day one.
Atlas
Across 2024 and 2025 FDA inspections, the biggest documentation failures involve data integrity and poor recordkeeping: missing batch records, altered lab data, weak CAPA investigations, and incomplete deviation files. This post covers what investigators are finding and how to fix it.
Atlas
The FDA is increasing inspections of foreign contract manufacturers, often without notice. Investigators focus on quality systems, data integrity, sterility controls, process validation, labs, supplier quality, and complaint handling. This guide breaks down what they look for and how pharma leaders can stay ready.
Atlas
The Model Context Protocol (MCP) is becoming the standard layer that lets LLMs and agentic AI interact safely with enterprise systems. This post covers the trends shaping MCP adoption in pharma, from governance and federated identity to regulator-ready audit trails and secure model orchestration.
Atlas
Atlas is a data-driven platform built for pharma and medical device quality teams. It covers 700,000+ FDA inspections since 2010, including 30,000+ Form 483s and 11,828 warning letters, all searchable in under a second with an AI copilot on top.
Atlas
The FDA's new internal generative-AI assistant ELSA (Enterprise Language Support Assistant) is an agency-wide tool launched in June 2025 to help reviewers, investigators, and scientists read, summarize, and prioritize large volumes of regulatory and safety data faster.
Atlas
Every compliance team wants to be proactive. They want to spot changes early, assess impact quickly, and act before an investigator raises an issue.
Atlas
AI is a practical capability for quality teams preparing for FDA inspections. Used well, it converts manual document review into reproducible queries, scores CAPA risk, and surfaces recurring observations across sites and suppliers.
Atlas
MCP (Model Context Protocol) is emerging as the backbone of AI and digital twin integration in pharma and medical devices. It links near-real-time equipment and quality data to AI models for predictive maintenance, process optimization, and QC.
Atlas
FDA Import Alerts can trigger detention without physical examination and freeze revenue at the border. This guide explains how the framework works, which root causes drive alerts, and the upstream quality and documentation practices manufacturers need to stay off the red list.
Atlas
Prepare as if inspections are always possible. QA teams must keep documentation current, systems validated, staff trained, and evidence traceable.
Atlas
Suppliers receive dozens of duplicate compliance data requests every quarter across different formats. This post covers why fragmentation is expensive, what buyers and suppliers can do to simplify it, and how supply chain monitoring tools cut repeat requests.
Atlas
Continuous supplier monitoring has replaced periodic audits for pharma and medical device manufacturers. This guide walks through every technology behind the shift, from IoT sensors and AI risk scoring to digital twins and control towers, with a five-phase implementation roadmap.
Atlas
Module 1 for the eCTD has been updated in both the US and EU during 2024 and 2025 with clearer validation criteria, controlled vocabularies, and machine-readable metadata to support the gradual global shift to eCTD v4.0.
Atlas
The FDA's 2025 AI/ML draft guidances shift from exploratory policy to operational expectations. Key changes include a risk-based credibility framework, lifecycle recommendations for AI-enabled device software, stronger data quality and bias requirements, and formalized predetermined change control plans.
Atlas
Repeat FDA violations keep showing up across drug, biologic, and device manufacturers because problems are systemic, including weak quality systems, sloppy data integrity, poor documentation, and inadequate CAPA and training.
Atlas
FDA inspections surged in FY2025 and unannounced foreign inspections went global. QA teams are using the Atlas AI copilot to see what each investigator focuses on, what they commonly cite, and how to prepare before they arrive on site.
Atlas
Supplier compliance is about speed, signals, and clear actions. This post covers why traditional methods fail, what real-time alerts actually do, and how to deploy monitoring, bulk upload, site-level tracking, and analysis features that reduce response time from weeks to days.
Atlas
CAPA is the backbone of pharma quality, and inspection findings keep citing weak investigations. This post shows how Atlas feeds inspection intelligence, investigator patterns, and enforcement signals into every stage of the CAPA lifecycle.
Atlas
In early 2025, New York banned DeepSeek, a Chinese AI assistant, from state government devices. Federal lawmakers followed. This post breaks down the national security concerns, the parallels with TikTok, and what the decision signals for foreign AI regulation in the US.
Atlas
Weak CAPA and investigation systems drive a high share of Form 483s and warning letters. This guide breaks down why investigations stop at "human error," how regulators read CAPA records, and the specific procedure, RCA, and governance fixes that make the system audit-ready.
Atlas
In May 2025 the FDA expanded unannounced inspections at foreign manufacturing sites. This piece breaks down the six reasons behind the shift, what the agency actually said, the investigator workforce reality, and how pharma and medical device manufacturers should respond.
Atlas
NIS2 raised the cybersecurity bar across the EU, but only 14% of organizations report being fully ready. This post covers the scope, why automation tools can't close the gap on their own, and a practical roadmap for governance, supplier oversight, and evidence.
